AIM: Canagliflozin is an SGLT2 inhibitor approved for the treatment of type-2 diabetes. A dynamic population pharmacokinetic-pharmacodynamic (PK/PD) model relating 24-h canagliflozin exposure profiles to effects on glycosylated haemoglobin was developed to compare the efficacy of once-daily and twice-daily dosing. METHODS: Data from two clinical studies, one with once-daily, and the other with twice-daily dosing of canagliflozin as add-on to metformin were used (n = 1347). An established population PK model was used to predict full 24-h profiles from measured trough concentrations and/or baseline covariates. The dynamic PK/PD model incorporated an Emax relationship between 24-h canagliflozin exposure and HbA1c-lowering with baseline HbA1c affecting the efficacy. RESULTS: Internal and external model validation demonstrated that the model adequately predicted HbA1c-lowering for canagliflozin once-daily and twice-daily dosing regimens. The differences in HbA1c reduction between the twice-daily and daily mean profiles were minimal (at most 0.023% for 100 mg total daily dose [TDD] and 0.011% for 300 mg TDD, up to week 26, increasing with time and decreasing with TDD) and not considered clinically meaningful. CONCLUSIONS: Simulations using this model demonstrated the absence of clinically meaningful between-regimen differences in efficacy, supported the regulatory approval of a canagliflozin-metformin immediate release fixed-dose combination tablet and alleviated the need for an additional clinical study.
RCT Entities:
AIM: Canagliflozin is an SGLT2 inhibitor approved for the treatment of type-2 diabetes. A dynamic population pharmacokinetic-pharmacodynamic (PK/PD) model relating 24-h canagliflozin exposure profiles to effects on glycosylated haemoglobin was developed to compare the efficacy of once-daily and twice-daily dosing. METHODS: Data from two clinical studies, one with once-daily, and the other with twice-daily dosing of canagliflozin as add-on to metformin were used (n = 1347). An established population PK model was used to predict full 24-h profiles from measured trough concentrations and/or baseline covariates. The dynamic PK/PD model incorporated an Emax relationship between 24-h canagliflozin exposure and HbA1c-lowering with baseline HbA1c affecting the efficacy. RESULTS: Internal and external model validation demonstrated that the model adequately predicted HbA1c-lowering for canagliflozin once-daily and twice-daily dosing regimens. The differences in HbA1c reduction between the twice-daily and daily mean profiles were minimal (at most 0.023% for 100 mg total daily dose [TDD] and 0.011% for 300 mg TDD, up to week 26, increasing with time and decreasing with TDD) and not considered clinically meaningful. CONCLUSIONS: Simulations using this model demonstrated the absence of clinically meaningful between-regimen differences in efficacy, supported the regulatory approval of a canagliflozin-metformin immediate release fixed-dose combination tablet and alleviated the need for an additional clinical study.
Authors: Zachary T Bloomgarden; Regina Dodis; Catherine M Viscoli; Eric S Holmboe; Silvio E Inzucchi Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Susan van Dieren; Joline W J Beulens; Yvonne T van der Schouw; Diederick E Grobbee; Bruce Neal Journal: Eur J Cardiovasc Prev Rehabil Date: 2010-05
Authors: Damayanthi Devineni; Christopher R Curtin; David Polidori; Maria J Gutierrez; Joseph Murphy; Sarah Rusch; Paul L Rothenberg Journal: J Clin Pharmacol Date: 2013-05-14 Impact factor: 3.126
Authors: K Stenlöf; W T Cefalu; K-A Kim; M Alba; K Usiskin; C Tong; W Canovatchel; G Meininger Journal: Diabetes Obes Metab Date: 2013-01-24 Impact factor: 6.577
Authors: Julio Rosenstock; Naresh Aggarwal; David Polidori; Yue Zhao; Deborah Arbit; Keith Usiskin; George Capuano; William Canovatchel Journal: Diabetes Care Date: 2012-04-09 Impact factor: 19.112
Authors: J-F Yale; G Bakris; B Cariou; D Yue; E David-Neto; L Xi; K Figueroa; E Wajs; K Usiskin; G Meininger Journal: Diabetes Obes Metab Date: 2013-03-28 Impact factor: 6.577
Authors: David M Nathan; John B Buse; Mayer B Davidson; Ele Ferrannini; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Diabetes Care Date: 2008-10-22 Impact factor: 17.152